Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma

Ji Hoon Kim, Joong Won Park, Dong Wook Koh, Woo Jin Lee, Chang Min Kim

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

Background/Aims: Treatment of patients with hepatocellular carcinoma (HCC) depends on the tumour extent and underlying liver function. Antiviral therapy with nucleoside/nucleotide analogues has been shown to be effective in improving the liver function of chronic hepatitis B (CHB) patients. We assessed whether lamivudine could induce biochemical and virological improvements in patients with hepatitis B virus-related HCC. Patients/Methods: Of 148 CHB patients treated with 100 mg/day lamivudine for at least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group). Biochemical and virological parameters were serially monitored. Results: Compared with the CHB group, the CHB/HCC group was older, had higher male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg) positivity (P < 0.05 each). The two groups showed similar cumulative rates of alanine aminotransferase normalization, HBV DNA seroconversion, HBeAg loss and viral breakthrough during 12 months of lamivudine treatment. After 12 months, the CHB/HCC group showed, relative to baseline, increased albumin levels (3.51 ± 0.5 vs. 3.72 ± 0.5mg/ml) and decreased ascites scores (1.63 ± 0.7 vs. 1.45 ± 0.6) and Child-Pugh scores (6.92 ± 1.9 vs. 6.02 ± 1.38) (P < 0.05 each). Conclusion: Lamivudine had comparable antiviral effects both in patients with CHB and CHB/HCC, and improved underlying liver function in the latter group. Treatment of HBV may increase the chance of curative treatments in patients with HBV-related HCC.

Original languageEnglish
Pages (from-to)203-207
Number of pages5
JournalLiver International
Volume29
Issue number2
DOIs
Publication statusPublished - 2009 Jan 19

Fingerprint

Lamivudine
Chronic Hepatitis B
Hepatitis B
Hepatitis B virus
Hepatocellular Carcinoma
Liver
Hepatitis B e Antigens
Antiviral Agents
Albumins
Therapeutics
DNA
Alanine Transaminase
Bilirubin
Nucleosides
Ascites
Liver Cirrhosis
Nucleotides

Keywords

  • Chronic hepatitis B
  • Efficacy
  • Hepatocellular carcinoma
  • Lamivudine
  • Liver function

ASJC Scopus subject areas

  • Hepatology

Cite this

Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. / Kim, Ji Hoon; Park, Joong Won; Koh, Dong Wook; Lee, Woo Jin; Kim, Chang Min.

In: Liver International, Vol. 29, No. 2, 19.01.2009, p. 203-207.

Research output: Contribution to journalArticle

Kim, Ji Hoon ; Park, Joong Won ; Koh, Dong Wook ; Lee, Woo Jin ; Kim, Chang Min. / Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma. In: Liver International. 2009 ; Vol. 29, No. 2. pp. 203-207.
@article{f4b6c0965bbc4a92b822079c40da4b42,
title = "Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma",
abstract = "Background/Aims: Treatment of patients with hepatocellular carcinoma (HCC) depends on the tumour extent and underlying liver function. Antiviral therapy with nucleoside/nucleotide analogues has been shown to be effective in improving the liver function of chronic hepatitis B (CHB) patients. We assessed whether lamivudine could induce biochemical and virological improvements in patients with hepatitis B virus-related HCC. Patients/Methods: Of 148 CHB patients treated with 100 mg/day lamivudine for at least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group). Biochemical and virological parameters were serially monitored. Results: Compared with the CHB group, the CHB/HCC group was older, had higher male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg) positivity (P < 0.05 each). The two groups showed similar cumulative rates of alanine aminotransferase normalization, HBV DNA seroconversion, HBeAg loss and viral breakthrough during 12 months of lamivudine treatment. After 12 months, the CHB/HCC group showed, relative to baseline, increased albumin levels (3.51 ± 0.5 vs. 3.72 ± 0.5mg/ml) and decreased ascites scores (1.63 ± 0.7 vs. 1.45 ± 0.6) and Child-Pugh scores (6.92 ± 1.9 vs. 6.02 ± 1.38) (P < 0.05 each). Conclusion: Lamivudine had comparable antiviral effects both in patients with CHB and CHB/HCC, and improved underlying liver function in the latter group. Treatment of HBV may increase the chance of curative treatments in patients with HBV-related HCC.",
keywords = "Chronic hepatitis B, Efficacy, Hepatocellular carcinoma, Lamivudine, Liver function",
author = "Kim, {Ji Hoon} and Park, {Joong Won} and Koh, {Dong Wook} and Lee, {Woo Jin} and Kim, {Chang Min}",
year = "2009",
month = "1",
day = "19",
doi = "10.1111/j.1478-3231.2008.01828.x",
language = "English",
volume = "29",
pages = "203--207",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Efficacy of lamivudine on hepatitis B viral status and liver function in patients with hepatitis B virus-related hepatocellular carcinoma

AU - Kim, Ji Hoon

AU - Park, Joong Won

AU - Koh, Dong Wook

AU - Lee, Woo Jin

AU - Kim, Chang Min

PY - 2009/1/19

Y1 - 2009/1/19

N2 - Background/Aims: Treatment of patients with hepatocellular carcinoma (HCC) depends on the tumour extent and underlying liver function. Antiviral therapy with nucleoside/nucleotide analogues has been shown to be effective in improving the liver function of chronic hepatitis B (CHB) patients. We assessed whether lamivudine could induce biochemical and virological improvements in patients with hepatitis B virus-related HCC. Patients/Methods: Of 148 CHB patients treated with 100 mg/day lamivudine for at least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group). Biochemical and virological parameters were serially monitored. Results: Compared with the CHB group, the CHB/HCC group was older, had higher male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg) positivity (P < 0.05 each). The two groups showed similar cumulative rates of alanine aminotransferase normalization, HBV DNA seroconversion, HBeAg loss and viral breakthrough during 12 months of lamivudine treatment. After 12 months, the CHB/HCC group showed, relative to baseline, increased albumin levels (3.51 ± 0.5 vs. 3.72 ± 0.5mg/ml) and decreased ascites scores (1.63 ± 0.7 vs. 1.45 ± 0.6) and Child-Pugh scores (6.92 ± 1.9 vs. 6.02 ± 1.38) (P < 0.05 each). Conclusion: Lamivudine had comparable antiviral effects both in patients with CHB and CHB/HCC, and improved underlying liver function in the latter group. Treatment of HBV may increase the chance of curative treatments in patients with HBV-related HCC.

AB - Background/Aims: Treatment of patients with hepatocellular carcinoma (HCC) depends on the tumour extent and underlying liver function. Antiviral therapy with nucleoside/nucleotide analogues has been shown to be effective in improving the liver function of chronic hepatitis B (CHB) patients. We assessed whether lamivudine could induce biochemical and virological improvements in patients with hepatitis B virus-related HCC. Patients/Methods: Of 148 CHB patients treated with 100 mg/day lamivudine for at least 6 months, 80 had HCC (CHB/HCC group) and 68 did not (CHB group). Biochemical and virological parameters were serially monitored. Results: Compared with the CHB group, the CHB/HCC group was older, had higher male predominance, bilirubin levels and liver cirrhosis rate, and lower albumin and hepatitis B virus (HBV) DNA levels and hepatitis B e antigen (HBeAg) positivity (P < 0.05 each). The two groups showed similar cumulative rates of alanine aminotransferase normalization, HBV DNA seroconversion, HBeAg loss and viral breakthrough during 12 months of lamivudine treatment. After 12 months, the CHB/HCC group showed, relative to baseline, increased albumin levels (3.51 ± 0.5 vs. 3.72 ± 0.5mg/ml) and decreased ascites scores (1.63 ± 0.7 vs. 1.45 ± 0.6) and Child-Pugh scores (6.92 ± 1.9 vs. 6.02 ± 1.38) (P < 0.05 each). Conclusion: Lamivudine had comparable antiviral effects both in patients with CHB and CHB/HCC, and improved underlying liver function in the latter group. Treatment of HBV may increase the chance of curative treatments in patients with HBV-related HCC.

KW - Chronic hepatitis B

KW - Efficacy

KW - Hepatocellular carcinoma

KW - Lamivudine

KW - Liver function

UR - http://www.scopus.com/inward/record.url?scp=58149510581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149510581&partnerID=8YFLogxK

U2 - 10.1111/j.1478-3231.2008.01828.x

DO - 10.1111/j.1478-3231.2008.01828.x

M3 - Article

VL - 29

SP - 203

EP - 207

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 2

ER -